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Abstract
Glioblastoma multiforme (GBM) is a highly lethal brain tumor. Due to resistance to current therapies, patient prognosis
remains poor and development of novel and effective GBM therapy is crucial. Glioma stem cells (GSCs) have gained
attention as a therapeutic target in GBM due to their relative resistance to current therapies and potent tumor-initiating
ability. Previously, we identified that the mitotic kinase maternal embryonic leucine-zipper kinase (MELK) is highly expressed
in GBM tissues, specifically in GSCs, and its expression is inversely correlated with the post-surgical survival period of GBM
patients. In addition, patient-derived GSCs depend on MELK for their survival and growth both in vitro and in vivo. Here, we
demonstrate evidence that the role of MELK in the GSC survival is specifically dependent on its kinase activity. With in silico
structure-based analysis for protein-compound interaction, we identified the small molecule Compound 1 (C1) is predicted
to bind to the kinase-active site of MELK protein. Elimination of MELK kinase activity was confirmed by in vitro kinase assay
in nano-molar concentrations. When patient-derived GSCs were treated with C1, they underwent mitotic arrest and
subsequent cellular apoptosis in vitro, a phenotype identical to that observed with shRNA-mediated MELK knockdown. In
addition, C1 treatment strongly induced tumor cell apoptosis in slice cultures of GBM surgical specimens and attenuated
growth of mouse intracranial tumors derived from GSCs in a dose-dependent manner. Lastly, C1 treatment sensitizes GSCs
to radiation treatment. Collectively, these data indicate that targeting MELK kinase activity is a promising approach to
attenuate GBM growth by eliminating GSCs in tumors.
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Introduction
Glioblastoma multiforme (GBM) is the most common and lethal
primary brain tumor in adults, and therefore, there is an urgent
need to develop novel therapeutic strategies that effectively target
therapy-resistant GBM cells. Among heterogeneous GBM cells
glioma stem cells (GSCs) represent a subpopulation of highly
tumorigenic cells that possess stem cell characteristics. While our
understanding of GSCs is evolving, there is a great deal of
evidence supporting the hypothesis that GSCs drive GBM
propagation and promote resistance to conventional therapies
such as radiation and chemotherapy [1–9].
Maternal embryonic leucine zipper kinase (MELK) is a serine/
threonine kinase that is highly expressed in various organ-specific
stem cells and cancers [10,11]. Furthermore, MELK expression is
correlated with a poor prognosis of a variety of cancers, including
GBM [10–13]. We previously demonstrated that MELK is
abundantly expressed in GBM with preferential expression in
GSCs and that targeting MELK-mediated pathways disrupt cell
cycle progression of GSCs in vitro and tumor growth in vivo,
suggesting that MELK is a clinically relevant molecular target for
GBM therapy [10,14–17]. To gain insights in the mechanisms of
action, we recently identified that MELK forms a protein complex
with the oncogenic transcription factors c-JUN and FOXM1 in
GSCs but not in non-GSCs or normal stem/progenitor cells
[18,19]. Further, both of these protein interactions are specifically
dependent on the MELK kinase domain [18]. These results
suggest that inhibition of the kinase activity of MELK could
disrupt key interactions with pivotal oncogenes in cancer cells,
while relatively sparing normal cells. In this study, we sought to
identify a novel small molecule that potently inhibits MELK kinase
activity.
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Materials and Methods
Ethics
Experiments using de-identified human tissue-derived materials
were carried out under the approved Institutional Review Board at
University of California, Los Angeles (UCLA) or Ohio State
University (OSU). Microarray studies were carried out at UCLA.
Primary samples collected at UCLA were de-identified and sent to
OSU for further studies. The OSU Institutional Review Board
approved this research study and waived the need for further
written informed consent from the participants. The name of this
protocol is Investigating Novel Therapeutic Strategies for Brain
Tumor Treatment and the approval number at OSU is
2005C0075. I Nakano serves as the Principal Investigator for this
approved protocol. All animal experimentation was performed at
OSU with the approval of the OSU Animal Research Committee,
following NIH guidelines.
Tissue Culture
Cells derived from 3 samples of GBM surgical tissues were
established in Dr. Harley Kornblum’s laboratory at UCLA and
were cultured as previously described [20]. Neurosphere cultures
derived from these 3 samples were designated as GBM146,
GBM157 and GBM206. GBM1600 cells were kindly provided by
Dr. Paul Mischel at UCLA and cultured in DMEM/F12 with
10% fetal bovine serum (FBS) (Sigma-Aldrich, MO)[16]. U87 and
U251 were obtained from ATCC (VA) and maintained in DMEM
(Life technologies, NY) with 10% FBS (Life technologies, NY).
cDNA Microarray
RNA was extracted from GBM sphere samples (GBM146,
GBM157, and GBM206) treated with 1 mM Siomycin A or
control (DMSO) for 24 hours with RNeasy Mini Kit according to
the manufactur’s protocol (Qiagen). RNA samples were subjected
to cluster (A) and canonical pathway analyses (D) by Ingenuity
software (Ingenuity Systems, www.ingenuity.com). The GEO
submission number for this microarray is GSE50227.
Flow Cytometry and Cell Sorting
Flow cytometry and cell sorting of CD133(+) and CD133(2)
cells from GBM spheres were performed using CD133 antibody
(clone: AC133) according to manufacturer’s protocol (Miltenyi
Biotec, CA) and as described previously [16,17].
In silico Docking Model and In vitro Kinase Assay
Using the structure-based virtual screening method, C1 was
identified as a potential MELK inhibitor from readily available
half a million commercial compounds. C1 compound was
subsequently validated via experimental enzyme assay as previ-
ously described [21,22]. Briefly, in order to account for the correct
binding of the ligands, crystal structural complexes of kinases for
each MELK inhibitor in the Protein Data Bank were sought and
similarity analysis based on SMILES was carried through the
National Center for Biotechnology Information. In total, 16
groups of templates, 4 structurally distinct MELK, were selected
for induced fit MELK conformational modeling on the basis of
backbone root-mean-square deviation of the binding site residues,
visual inspection of the p-loop, and individual docking perfor-
mance. Furthermore, the templates were selected using a MELK
domain sequence with the Basic Local Alignment Search Tool.
Using these conformers and known inhibitors, all the docking and
virtual screening calculations were performed with the Virtual
Screening Workflow script and selected the final 3 protein models.
A total of 30 compounds of varying potency with at least 25%
inhibition of MELK activity at 1 mM were collected and
downloaded the structures from readily available half a million
commercial compounds. With the screening to the ATP binding
pocket of all 3 selected conformers using Glide HTVS docking, the
top 10% of the compounds were carried forward by the more
exhaustive Glide SP docking algorithm. The most highly scored
10% of the SP docked compounds were narrowed down and
finally the 3 compounds, showed a pair of hydrogen bonds with
the hinge residues, were selected. Subsequently, the 3 compounds
were validated via experimental enzyme assays, C1 was the most
selective (Kd= 18 mM), which showed no or minimal activity to
the other kinases. Similarity search to the Chemical Abstracts
Service database was performed in order to check the novelty of
this computationally discovered MELK inhibitor candidate.
GBM Slice Culture
GBM surgical tissues of 2 patients were received immediately
after surgery from the Department of Pathology at OSU and they
were histopathologically diagnosed as GBM by the assigned
neuro-pathologists. Serial sections of the surgical specimens were
cut to create tumor blocks (10 mm in diameter) and these blocks
were transferred into 6 well plates as described previously [23].
Tumor blocks were then injected with either DMSO (5%) or C1
(2.5 nM) and incubated for 16 hours at 37uC in humidified air
containing 5% CO2. After incubation we confirmed that the
tumor slice cultures retain the histopathological characteristics of
GBM. These treated tissues were fixed with 10 mL of 10% v/v
formalin for 24 hours and processed for paraffin-embedded
sections (4 mm thickness) for immunohistochemistry.
Xenograft
Ten thousand GBM157 sphere cells in 5 ml of phosphate
buffered saline (PBS) were injected intracranially into immuno-
compromised mice (n = 16) (Athymic NCr-nu/nu; National
Cancer Institute, Strain Code 01B74) according to the methods
described previously [19,23]. At day 7 after transplantation,
varying doses of C1 (2.5 pmol: n = 3 25 pmol: n = 4, 250 pmol:
n = 5) or DMSO (n=4) were injected into tumor cavities. Three
days following C1 or DMSO injection, we sacrificed 3 treated
mice (DMSO: n= 1, 25 pmol: n = 1, 250 pmol: n = 1) and stained
the brains with the proliferation marker Ki-67. For analysis of
tumor growth, 13 mice were sacrificed at 8 weeks after
transplantation. The tissues were fixed with ice cold 4%
paraformaldehyde in PBS overnight, sunk in 20% sucrose in
PBS, and stored at 280uC until use. Sections were subsequently
cryoprotected, sectioned at 20 mm and stained with the human-
specific Nestin for measuring the tumor size according with the
same protocol that we used in our previous study [16,25].
Immunocytochemistry and Immunohistochemistory
Studies were performed as described previously [16,17,19]. The
primary antibody for MELK (1:200, Sigma-Aldrich, Missouri) was
used to visualize the fluorescent signals using the following
secondary antibodies: Alexa 488 or Alexa 555 (1:1000, Cell
Signaling Technology, MA). Specificity was determined using no-
primary control slides. For immunohistochemistry, the following
primary antibodies were used: Nestin (anti-Nestin, clone 10C2,
1:200, mouse monoclonal antibody, MAB5326, MA) and Ki67
(anti-Human Ki-67, clone MIB-1, 1:1, mouse monoclonal
antibody, Dako, Denmark). The Envision system (Dako) followed
by Diaminobenzidine (DAB) method was used for detection of
primary antibody according the manufacturer’s protocol. For
paraffin-embedded slides, hematoxylin was used as a nuclear
MELK Kinase Inhibitor
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counterstain. IHC scoring was performed using automated digital
image analysis (ImageJ).
Time-lapsed Microscopy
U251 cells were transfected with the vector E-GFP-N1 using
lipofectamine (Invitrogen) according to the manufacturer’s proto-
col. Cells were selected by gentamicin (100 mg/ml), seeded on a 2-
wells Lab-Tek chambered coverglass (Nalge Nunc International),
and maintained under standard culture conditions (37uC, 5%
CO2) for 22 to 24 hours. One mM of C1 or DMSO was added to
the cell culture just before imaging. To avoid drug combinations,
cells were only synchronized by trypsination around 24 hours
before imaging. Images were acquired on a Zeiss dynascope
confocal microscope (LSM 710) equipped for alive cells (37uC, 5%
CO2) by using a Plan-Apochromat 40 X-water immersion
objective. The positions of the mitotic cells on the stage were
registered and therefore, these cells were imaged continuously.
None of the followed mitotic cells divided in two daughter cells.
Control and treated cells were imaged simultaneously. Then, the
Lab-Teck was kept under normal culture conditions and cells were
fixed upon 72 hours of treatment by 4% paraformaldehyde and
nuclei stained by Hoechst 3342. Images were recorded with the
same equipment as above but at room temperature and analyzed
with the Zen software provided by Zeiss. Only one cell line was
imaged since the behavior of the cells upon C1 treatment is similar
to what was previously observed in HeLa, Hek or H358 cells
[26,27]. Three independent experiments were conducted and 10
to 15 fields were followed in each.
Apoptosis Assay
U251 cells treated with either C1 or DMSO for 48 hours was
analyzed by flow cytometry with Annexin V antibody and
Propidium Iodide (Life technologies, NY) using the Apoptosis
Detection Kit (R&D Systems, MN) according to the manufactur-
er’s instructions. Data was confirmed by 3 independent experi-
ments.
Neurosphere Formation Assay and Radiosensitivity Assay
Neurosphere formation assay and radiosensitivity assay were
performed as described previously [16,17,19].
Statistical Analysis
Statistical analysis was performed using the SPSS17 Statistics
software (IBM Corporation, NY) using one-way ANOVA and
student’s T test. A probability of p,0.05 was considered to be
significant. All the data are shown in mean6 standard error of the
mean (SEM).
Results
Siomycin a Treatment of GSCs Results in Downregulation
of Genes in the DNA Damage-induced Repair Pathway
Previously we demonstrated that the thiazole antibiotic
Siomycin A attenuates a MELK-mediated signaling, thereby
diminishing GSC growth in vitro and in vivo [16]. Here we first
sought to determine the downstream pathways in GSCs that are
suppressed by Siomycin A treatment. We performed cDNA
microarray with 3 well-characterized GBM neurosphere samples
(GBM146, GBM157, and GBM206) [10] treated with either
1 mM of Siomycin A or vehicle (DMSO) for 48 hours. Unbiased
cluster analysis separated these 3 samples into 2 groups; either
DMSO-treated or Siomycin A-treated GBM neurospheres
(Fig. 1A). Consistent with our previously published quantitative
reverse transcriptase (qRT)-PCR [19], Siomycin A significantly
downregulated MELK as well as its binding partner FOXM1
(Fig. 1B). The other downregulated genes included mitotic genes
such as Aurora A/B and Survivin (Fig. 1B and C). Pathway
analysis using Ingenuity indicated that the most downregulated
pathway is the DNA damage-induced ATM/ATR pathway; a
pathway that regulates the G2/M checkpoint (Fig. 1D). In
addition, the transcriptional p53 signaling pathway was also
significantly downregulated by Siomycin A treatment (Fig. 1D),
supporting our previous study that demonstrated MELK action is
mediated, at least in part, through inhibition of p53 pathway [18].
Kinase Activity of MELK is Essential for GSC Survival
Next we investigated whether the function of MELK in GSCs
specifically depends on its kinase activity. To address this question,
we combined lentiviral infection of MELK shRNA vector, to
downregulate endogenous MELK protein, with overexpression of
MELK wild type or the kinase dead version of MELK (MELK
D150A) [28]. Flow cytometry with Annexin V (AV) and
Propidium Iodide (PI) demonstrated that GBM1600 spheres
infected with MELK shRNA have more cells in early (AV(+),
PI(2)) and late (AV(+), PI(+)) stages of apoptosis, compared to the
control shRNA infected cells (Fig. 2A). We then introduced
MELK wild type or D150A cDNA into these infected cells. As a
control, we used GFP-overexpression vector. When wildtype
MELK was restored in MELK shRNA infected GBM1600
spheres, we observed a partial reversal of the effects on apoptosis
(AV(+), PI(+) cells; 30.7% in the control samples vs. 15.4% in
MELK wild type samples) [18]. In contrast, overexpression of
MELK D150A failed to rescue the effects of MELK knockdown
(AV(+); PI(+) cells; 37.0% in MELK D150A sample), indicating
that this mutant MELK lacks the ability to recover MELK
elimination-induced cell death. Given that our previous observa-
tion that the D150 residue of MELK is required for the interaction
of MELK protein with the oncogenic transcriptional factors c-JUN
and FOXM1 in a cancer-specific manner [18,19], it is likely that
the kinase domain is essential for MELK-driven GSC survival.
Identification of C1 as an Inhibitor for Mitotic Kinases
Including MELK
The above data raised a possibility that the kinase domain of
MELK is a potential therapeutic target for GBM. We therefore
sought to discover small molecules that specifically inhibit its
kinase activity. To this end, we performed an in silico screening of
small molecules and identified a benzo[e]pyridoindole, C1
(Fig. 2B), as a multi-kinase inhibitor with significant activity
against the mitotic kinases, MELK and Aurora B. Effects of C1 on
other kinases exhibited substantially lower potency [21]. Comput-
er-based molecular structure analysis supported the predicted
docking of C1 to the ATP-binding site of MELK protein (Fig. 2C).
The inhibition of MELK kinase activity by C1 was further
validated, as we found that compound C1 inhibited the kinase
activity of recombinant MELK protein with an IC50 of 42 nM
in vitro (Fig. 2D).
C1 Treatment Inhibits GSCs to a Greater Extent than Non-
GSCs In vitro
Next, we sought to assess the sensitivity of GSCs to C1 in vitro.
First, we compared the effects of C1 treatment on neurosphere
formation from patient-derived GBM cells and normal neural
progenitors [17]. We incubated the 3 GSC samples (GBM146,
GBM157, and GBM206) and normal neural progenitors (16wf)
with varying concentrations of C1 to measure the impact on
MELK Kinase Inhibitor
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neurosphere formation. C1 treatment attenuated neurosphere
formation of all 3 GBM samples at substantially lower doses
(GBM146: 440 nM; GBM157: 370 nM; GBM206: 370 nM) than
normal progenitors (16wf: 790 nM)(Fig. 3A).
We then performed FACS analysis with GSCs treated with
either C1 or DMSO, as the expression of the cell surface CD133 is
well-recognized as a surrogate, but not definitive, marker for GSCs
[24,29,30]. Following separation of GBM157 cells into CD133(+)
and CD133(2) populations by cell sorter, individual cell popula-
tions were separately treated with 1mM of C1 or DMSO under the
identical serum-free conditions for 48 hours. CD133(+) tumor cells
with C1 treatment showed significant reduction of the sphere
number compared with the DMSO-treated cells. On the contrary
this C1-induced cell number reduction was not apparently
observed in CD133(2) tumor cells (p,0.01; Fig. 3B). Collectively,
C1 has more potent inhibitory effect on GSC growth compared to
the growth of non-GSCs or normal progenitors in vitro.
C1 Induces Apoptotic Cell Death in Organotypic Slice
Cultures of GBM Surgical Specimens
Organotypic slice culture of tumor tissues is one experimental
model readily available to assess the influence of drug treatment on
tumor cells in situ without significantly destroying the tumor
microenvironment [31]. We performed intratumoral injection of
C1 or DMSO using 2 patient-derived slice cultures of GBM
tumors (Fig. 3C). Immunohistochemistry for Ki-67 exhibited the
presence of abundant proliferating tumor cells in the DMSO
treated samples but not in the C1 treated ones (p,0.0026; Fig. 3D),
suggesting that C1 treatment suppressed GBM cell proliferation
in situ. We then assessed the effect of C1 injection on sphere-
forming GSCs within these slice cultures. After the C1-treated or
DMSO-treated slice cultures were dissociated into single cells, we
performed neurosphere formation assay. As shown in Fig. 3E, we
found the significant reduction both of the number of neuro-
spheres and the total cell numbers by C1 treatment in both cases
Figure 1. Genes in the DNA damage-induced response pathway are downregulated in Siomycin A-treated GSCs. cDNA microarray of
GBM146, GBM157, and GBM206 samples treated with 1 mM Siomycin A or control (DMSO) were subjected to cluster (A) and canonical pathway
analyses (D) using Ingenuity software. Log (pValue) of most significantly downregulated pathways are shown (p,0.05). The most downregulated and
upregulated genes in Siomycin A-treated GSCs are shown in (B) and (C), respectively. Expression of FOXM1, MELK, Aurora A/B, and Survivin were
significantly decreased by Siomycin A treatment compared with DMSO treatment.
doi:10.1371/journal.pone.0092546.g001
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(p,0.01). These data suggest that C1 has a potent inhibitory effect
on the GBM cell proliferation and GSC growth under the
condition of a relatively preserved microenvironment for GBM
tumors.
C1 Inhibits GBM Cell Growth In vivo
Given the potent inhibitory effects of C1 on GSCs in vitro and
ex vivo, we next investigated the effect of C1 treatment on mouse
models of GBM in vivo. Following transplantation of GBM157 cells
into immunocompromised mouse brains, we injected C1 at day 7
with quantities of 2.5 pmol, 25 pmol, and 250 pmol into the
tumor cavities (Fig. 3F). At day 3 post-C1 injection, we observed a
substantial decrease in proliferating GBM157 cells, as evidenced
by far fewer cells labeled with Ki-67(+) in C1-treated (25 pmol and
250 pmol) tumors than DMSO-treated (40% in DMSO-treated
tumors vs. 32% in C1-treated tumors (25 pmol); Fig. 3G).
With the other set of mice harboring GBM157-derived
intracranial tumors, we measured tumor sizes at 8 weeks post-
transplantation. While there was only a marginal difference in
tumor sizes between the control and C1 treatment at 2.5 pmol,
tumors treated with C1 at both 25 pmol and 250 pmol exhibited a
3-fold decrease in size compared to the control (n = 7, p,0.0001;
Fig. 3H and I). These results suggest that intra-tumoral treatment
with C1 diminishes the in vivo growth of GSC-derived tumors in
mouse brains.
C1 Treatment Induces Early Mitotic Exit and Subsequent
Mitotic Catastrophe and Cell Death of GSCs
Next, we investigated the mechanism of cell cycle arrest induced
by MELK kinase inhibition in 2 GBM-derived cell lines, U87 and
U251. We first confirmed that C1 decreases their growth in vitro.
With both cell lines, the total viable cells were significantly
decreased by C1 treatment compared to DMSO-treated cells
(U87: p,0.001, U251: p,0.0001; Fig. 4A). We then performed
time-lapsed immunocytochemistry with C1-treated U251 cells
expressing GFP. The top panel in Fig. 4B (left side is treated with
DMSO, right side with C1) displayed mitotic cells readily dividing
and giving rise to two daughter cells (arrows and arrowheads). C1-
treated mitotic U251 cells could not undergo anaphase and
prematurely escaped from mitosis, as evidenced by the round cell
spread on the substrate at 1 hour 40 min (cell focused from former
field) post-treatment. As showed in the bottom panel of Fig. 4B,
C1-treated cells at 72 hours formed polyploid cells with multiple
abnormal micronuclei within single cells, unlike the control cells
exhibiting normal, euploid nuclei. This phenomenon is known as
‘‘mitotic catastrophe,’’ which irreversibly drives cells into apoptosis,
necrosis, or senescence [32]. In contrast, when U251 cells were
treated with temozolomide (TMZ), the current first-line chemo-
therapy for GBM, cell growth was attenuated without affecting
mitotic division (data not shown). Collectively these data suggest
that the mechanism of cell death by C1 is distinct from that of
TMZ.
Since C1 is a multi-kinase inhibitor, we then sought to
determine the major molecular target of C1 in GSCs. We
postulated that if C1 attenuates GSC survival mainly through
MELK kinase inhibition, the phenotype of C1-treated GSCs
should be identical to that of shRNA-mediated MELK elimina-
tion. Previously, we found that MELK knockdown prevents GSCs
from proper mitotic progression, resulting in accumulation of
tumor cells in the G2/M phase, generation of polyploid cells with
multiple micronuclei, and subsequent apoptotic cell death [17,33].
We monitored C1-treated GBM1600 cells from pre-mitosis phase
until mitotic completion. As expected, GBM1600 cells at pre-
mitosis phase express high levels of MELK protein (Fig. 4C, left
panel). We then followed the effects of C1 through karyokinesis
and cytokinesis of GBM1600 cells. These C1 treated GBM1600
cells demonstrated micronucleated, chromatin condensation (signs
of apoptosis) and asymmetric division (Fig. 4C, middle and right
panels). DMSO-treated cells, on the other hand, showed round
chromatin and homogenous cell size and figures. To support these
data, cell cycle analysis with PI showed the accumulation of C1-
treated GBM1600 GSCs at the G2/M phase (62.7% with C1
treatment vs. 19.3% with DMSO treatment; Fig. 4D). To
determine the subsequent cell fate of C1 treated cells, we
performed FACS analysis with U251 cells using Annexin V and
PI (Fig. 4E). Both early and late apoptotic fractions were
significantly increased in C1-treated cells in a dose-dependent
manner (p,0.001; Fig. 4E). Taken together, these data indicate
that C1 treatment induces failure of mitotic progression to
undergo anaphase and G2/M arrest of GSCs. These effects
subsequently promote early mitotic exit, metaphase-associated
mitotic catastrophe, and subsequent apoptotic cell death.
C1 Sensitizes GSCs to Radiation Treatment
Irradiation is the current first line post-surgical therapy for
GBM patients. Nonetheless, the survival benefit for GBM patients
of radiation treatment is no greater than 3 months [34,35]. One
potential reason for the limited efficacy of this treatment is the
rapid induction of the DNA damage repair genes and proteins in
tumor cells [4]. In particular, GSCs are known to upregulate these
Figure 2. The kinase activity plays an essential role in the
action of MELK on GSCs and identification of C1 as a MELK
kinase inhibitor. A, GBM1600 spheres transfected with MELK wild
type vector or MELK kinase dead (MELK D150A) vector were subjected
to transfection of shRNA for MELK to eliminate endogenous MELK. Non-
targeting shRNA and GFP vector were used as controls. The proportion
of apoptosis at 48 hours post-transfection was analyzed by flow
cytometry using Annexin V antibody and Propidium Iodide. B, Schema
showing the chemical structure of the benzo[e]pyridoindole, Com-
pound 1 (C1). C, In silico modeling of C1 predicted binding to MELK
through hydrogen bonding with the backbone residues of the hinge
region of the ATP binding pocket (Glu87, Tyr88, Cys89) by computa-
tional analysis. A pair of hinge residue hydrogen bonds makes favorable
hydrophobic interactions. D, A ten-dose curve allows the determination
of the in vitro efficiency of C1 towards the recombinant kinase (IC50:
concentration of C1 that inhibits kinase activity by 50%). Solid black
squares indicate individual data points.
doi:10.1371/journal.pone.0092546.g002
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Figure 3. C1 treatment inhibits GSC proliferation in vitro and in vivo. A, Graph of neurosphere forming assay indicating the relative
neurosphere numbers of C1-treated patient-derived GBM samples (GBM146, GBM157, and GBM206) and normal neural progenitors (16wf). B,
CD133(+) and (2) cells, separated from GBM157-derived sphere cultures, were treated with 1 mM C1 or DMSO (control) under the identical serum-free
conditions for 48 hours. The effect on CD133(+) cells was assessed by the neurosphere number per well, and the effect on CD133(2) cells was
assessed by the % change of the total cell number in comparison to the control sample. C, Schematic showing organotypic slice cultures explanted
GBM tissues and treated with C1 or DMSO (control) for 16 hours and evaluated with H&E, Ki67, and Nestin staining. D, Immunohistochemistry of C1-
or DMSO-treated GBM slice cultures with anti-Ki-67 monoclonal antibody (Original magnification, 6200). E, Graph indicating the numbers of
neurospheres (left) or total cells (right) in serum-free medium derived from C1- or DMSO-treated slice cultures for 16 hours. F, Schematic drawing of
the effect of C1 treatment for the mouse intracranial GBM models derived from GSCs. Cells from GBM157 spheres were injected intracranially into
immunocompromised mice (C1 mice: n = 4, control mice: n = 12). At day 7 post transplantation, C1 was injected intratumorally at quantities of
2.5 pmol (n = 3), 25 pmol (n = 4), or 250 pmol (n = 5). G, Representative images for immunohistochemistry with Ki-67 staining of GBM slice cultures
treated with 25 pmol C1 or DMSO at day 10 of treatment. Ki-67 positive cells in each group were analyzed automated digital image analysis (Original
magnification, 6200). H, Representative images for immunohistochemistry with human-specific Nestin antibody using GBM157-derived mouse
intracranial tumors treated with varying doses of C1 or DMSO intratumoral injection (bar: 1 mm). I, Graph indicates tumor sizes in each group as
determined by Nestin staining intensities analyzed using automated digital image analysis.
doi:10.1371/journal.pone.0092546.g003
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Figure 4. C1 treatment accumulates GSCs in G2/M and triggers subsequent mitotic catastrophe. A, Proliferation assays on two
glioblastoma cell lines (U87 and U251). U87 and U251 cells were treated with 5.7 mM C1 or DMSO. Cells were trypsinized and estimated by counting,
in duplicate, after 72 h of treatment. Two different experiments were conducted with similar results. B, Time-Lapse on mitotic U251 cells stably
expressing GFP was performed in the absence (DMSO) or in the presence of C1 (at 1 mM). The compound was added to the cell culture just before
imaging and then cells were continuously imaged. Three independent experiments were conducted and 10 to 15 fields were followed in each. None
of the followed mitotic cells divided in two daughter cells. Representative field is imaged, DNA is in blue and the merge shows GFP and DNA. Several
polyploid cells were present in the image. Arrows and arrowheads in upper panels of DMSO and C1- treated cell indicate the same cells through time-
lapse. The elapse times are indicated on each photo, in some assays, a zoom of one cell is shown (the red bar represents 5 mm) this cell is present on
the former field and labelled with an arrow). Images in bottom panels show DNA only (left) and DNA overlap with GFP (right) after 72-hour treatment
with DMSO or C1 (the red bars on each panel represent 20 mm). Arrows in the bottom panel of C1-treated cells indicate mitotic catastrophe by C1
treatment. C, Pictures demonstrate pre-mitotic phase (left panel), mitotic (mid panel) process by full karyokinesis and cytokinesis and after cell
division (right panel). MELK expression was determined with immunocytochemistry of GBM1600 cells with anti-MELK antibody (red), chromatin
staining with Hoechst stain (blue). Picture of pre-mitosis shows GBM1600 cells highly expressed MELK at pre-mitosis phase (4006magnification).
Then GBM1600 cells were treated with 5 mM C1 or control and were subjected to immunocytochemistry 3 days later with anti-MELK and chromatin
staining (6406magnification). Data were confirmed by three independent experiments. C1 treated cells are micronucleated at metaphase and
followed multinuclear chromatin condensation (mid panel). Right panel show multinuclear asymmetric divided chromatin of C1 treated cell
compared with DMSO treated cell. D, Flow cytometric analysis of C1- and DMSO-treated GBM1600 cells with Propidium Iodide at 3 days after
treatment shows 62.7% of C1-treated cells resulted in the G2/M arrest, whereas the control cells have 19.3% of the G2/M arrested cells.E, Graph
indicating the proportions of live, early apoptotic, and late apoptotic U251 cells with varying doses of C1 or DMSO.
doi:10.1371/journal.pone.0092546.g004
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DNA repair genes more efficiently than non-GSCs, which may
partially explain their pronounced radioresistance [4,36]. Since we
found that inhibition of MELK-mediated pathway potently
suppressed the DNA damage repair pathway in GSCs (Fig. 1D),
we hypothesized that C1 treatment combined with radiation
would have a greater efficacy over radiation alone. To address this
question, we used radiation treatment at sub-lethal doses (2Gy and
4Gy) for GSCs with or without C1 treatment (Fig. 5). While
radiation alone did not noticeably affect GSC survival at the
indicated doses, the combination with 1mM of C1 treatment
resulted in a significant reduction in the GSC growth (p,0.0001),
indicating that C1 treatment sensitizes GSCs to radiation-induced
cell death in vitro.
Discussion
In this study, we demonstrated that MELK acts on GSC
survival through its kinase activity. We performed the computa-
tional structure analysis of MELK protein to determine the ATP
binding region of this kinase. Using this information, we identified
C1 as a kinase inhibitor with substantial potency against MELK.
C1 treatment not only induced G2/M arrest and subsequent
mitotic catastrophe of GSCs in vitro, but also inhibited the growth
of GSC-derived tumors in vivo. Finally, we found that C1
treatment sensitizes GSCs to radiation-induced cell death,
supporting C1 as an attractive molecule-targeting therapy to
combine with current standard protocols of GBM treatment.
Our study contributes several novel findings to the current
understanding of the GBM pathophysiology. To our knowledge,
we present the first pre-clinical data for MELK kinase inhibition-
mediated suppression of GBM cell growth in vivo using a small
molecule kinase inhibitor. Previously, we found that the oxo-group
of C1 is necessary for kinase inhibitory activity [27]. Our in silico
model predicted that the oxo-group of C1 forms a strong hydrogen
bond with the Tyr88 residue of the ATP-binding triplet domain,
confirming our earlier report [21]. Our study therefore illustrates
that pharmacological inhibition of kinase activity at the ATP
binding site has very attractive therapeutic potential and strongly
warrants further study and drug development. However, similarity
of the structure of the ATP binding site has been noticed with
various protein kinases. In fact, our prior study exhibited that C1
inhibits multiple protein kinases with potent effects on not only
MELK but also Aurora kinases and Chk2 with the highest
affinities towards Aurora B and MELK [21]. With the current
dataset, we cannot draw a definitive conclusion that the potent
effect on GSCs by C1 treatment is solely due to MELK inhibition.
Both Aurora B and MELK are mitotic kinases, and the relative
inhibition of each by C1 is indistinguishable. However, the
selectivity towards CD133(+) cells in this study may suggest that
MELK inhibition predominantly contributes to C1 efficacy in
GSCs [10,16]. The individual effects of C1 on these kinases aside,
we found that inhibition of the MELK-mediated pathway also
suppresses expression of Aurora kinases (Fig. 1B and C). In
addition, we recently revealed that the oncogenic transcription
factor FOXM1 is a substrate for MELK specifically in GSCs.
Given that Aurora kinases are known downstream targets of
FOXM1, multi-kinase inhibition would provide better efficacy
with lower doses to avoid unwanted toxic effects on normal orgains
[19]. Further work is definitely needed to determine the
contributions of Aurora kinases and other protein kinases to
GBM pathogenesis and to clarify the full scope of C1 target
molecules.
Given that mutations in the kinase domain or in other
molecular elements of MELK do not appear to be a frequent
event in cancers, the distinct function of MELK in normal and
oncogenic stem cells is likely to be epigenetic. Several recent
studies, including our own, have implicated MELK in cell cycle
regulation [37,38], successful cell division [39], and suppression of
apoptosis [16,40,41], making it entirely possible that MELK
contributes to tumor initiation and propagation through molecular
interactions with deregulated oncogenes and/or tumor suppressor
genes. In support of this notion, we recently demonstrated that a
JNK pathway-driven interaction of MELK with another tran-
scription factor/oncoprotein c-JUN is essential for GSC survival,
proliferation, and radioresistance in a p53 dependent manner
[18]. Introducing a point mutation in MELK protein at the D150
residue, which is required for proper kinase activity [28],
attenuated the protein complex formation with c-JUN. Further-
more, this interaction with c-JUN was unique to GSCs and was
not found in normal neural progenitors. Collectively, it is possible
that C1 interrupts the oncogenic JNK signaling cascade through
inhibition of MELK kinase activity and the resulting interaction
with c-JUN. Given that JNK signaling orchestrates a variety of
cellular processes, pharmacological inhibition of MELK, a more
downstream and possibly cancer-specific protein, may lead to
fewer off-target effects and greater specificity in targeting cancer
cells. Further studies are required to elucidate this possibility.
The potent radioresistance of GSCs has been partly attributed
to upregulation of the ATM/ATR DNA damage response
pathway [42,43]. In this study, we found that the greatest effect
of MELK signaling inhibition was on the ATM/ATR DNA
damage response pathway and C1 treatment radiosensitizes GBM
cells at least in vitro. Recently, Golding et al. reported that ATM
inhibition effectively radiosensitizes GBM cells without harming
normal neural progenitor cells [44]. Further, Raso et al.
demonstrated that radiosensization through ATM inhibition
occurs preferentially in GSCs but not in non-GSCs [45]. We
previously demonstrated that treatment of GSCs with Siomycin A
reduces GSC-derived tumor growth in vivo without causing a
noticeable harmful effect on normal brain cells [16]. Taken
together, MELK inhibition may attenuate radiation-induced
ATM/ATR activation in GSCs that are essential for their role
in the DNA damage repair and survival.
Regarding the clinical application of C1 for GBM therapeutics,
some open questions remain. In fact, the efficacy of chemotherapy
of brain malignancies is often hampered by the presence of the
blood-brain barrier (BBB). From the point of molecular weight,
the size calculated from the structure of C1 is 293 Da, which is
Figure 5. C1 sensitizes GBM cells to radiation-induced cell
death, in vitro. Graph indicating the relative total cell numbers after
monotherapy (1 mM C1 or radiation) or after combination therapy. Cells
treated with combination therapy were radiated (2Gy or 4Gy) at 24
hours post-C1 treatment and the subsequent total cell numbers were
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presumably small enough to penetrate the BBB. However, the
permeability of the BBB is not solely dependent on the molecular
size but also affected by several kinds of drug property and
circumstances. Given the potent effect of C1 treatment on mouse
GBM-like tumor models in vivo, it is attempted to evaluate the
permeability of the BBB and bioavailablity/stability of C1 in vivo.
In conclusion, our data indicate that C1 is a novel inhibitor for
protein kinases with substantial inhibitory effect on MELK. This
study suggests that pharmacological inhibition of MELK kinase
activity represents an attractive therapeutic approach for GBM
that may overcome the resistance seen after current, standard
treatment protocols. We postulate that C1 may also effectively
treat a variety of cancers with elevated activation of MELK.
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